Mianserin

Antidepressant

Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 420283195
| IUPAC name = (±) 2 methyl 1,2,3,4,10,14b hexahydrodibenzo[c,f]pyrazino[1,2 a]azepine
| image = Mianserin 2D structure. svg
| width = 175px
| image2 = Mianserin ball and stick model. png
| width2 = 175px

| tradename = Tolvon, others
| pregnancy AU = B2
| pregnancy US =
| legal AU = S4
| legal BR = C1
| legal BR comment =
| legal UK = POM
| legal US =
| routes of administration = By mouth

| bioavailability = 20–30%
| protein bound = 95% It is a tetracyclic antidepressant (TeCA). Mianserin is closely related to mirtazapine, both chemically and in terms of its actions and effects, although there are significant differences between the two drugs.

Mianserin at higher doses (30–90mg/day) is used for the treatment of major depressive disorder.

It should not be given, except if based on clinical need and under strict medical supervision, to people younger than 18 years old, as it can increase the risk of suicide attempts and suicidal thinking, and it can increase aggressiveness. decreased appetite or anorexia, insomnia, diarrhea, nausea and vomiting, and flu like symptoms, such as allergies or pruritus, among others.

Overdose of mianserin is known to produce sedation, coma, hypotension or hypertension, tachycardia, and QT interval prolongation.

The bioavailability of mianserin is 20 to 30%. (S) (+) Mianserin is approximately 200–300 times more active than its enantiomer (R) (−) mianserin; hence, the activity of mianserin lies in the (S) (+) isomer.

It was developed but not discovered by Organon International; the first patents were issued in The Netherlands in 1967, and it was launched in France in 1979 under the brand name Athymil, and soon thereafter in the UK as Norval. Investigators conducting clinical trials in the US submitted fraudulent data, and it was never approved in the US. Mianserin was one of the first antidepressants to reach the UK market that was less dangerous than the tricyclic antidepressants in overdose; as of 2012 it was not prescribed much in the UK.

Mianserin is the English and German generic name of the drug and its and , while mianserin hydrochloride is its , , and Its generic name in French and its are miansérine, in Spanish and Italian and its are mianserina, and in Latin is mianserinum.

Mianserin is marketed in many countries mainly under the brand name Tolvon. It is also available throughout the world under a variety of other brand names including Athymil, Bonserin, Bolvidon, Deprevon, Lantanon, Lerivon, Lumin, Miansan, Serelan, Tetramide, and Tolvin among others. A mianserin generic drug received approval in May 1996 and is available in Australia.

The use of mianserin to help people with schizophrenia who are being treated with antipsychotics has been studied in clinical trials; the outcome is unclear.